Nintedanib inhibits VEGFR, FGFR, and PDGFR simultaneously and demonstrated moderate efficacy in NSCLC but was frequently associated with diarrhea, hepatotoxicity, and vascular-related adverse events [128,219]. The gene discussed is KDR; the disease is non-small cell lung carcinoma.